Neera Clase to Become Tarsus Chief Commercial Officer
The Irvine-based pharmaceutical company taps veteran leader to oversee commercial strategy and pipeline growth.
Updated on Oct. 28, 2026 in People
Live Poll
Do you trust that new corporate leadership will prioritize patient access to essential prescription medications?
Tarsus Pharmaceuticals will appoint Neera Clase as its new Chief Commercial Officer effective November 1, 2026. Clase, who has served as the company's interim leader in the role since July 2026, will manage commercial planning for retina programs.
Why it matters
Clase's appointment marks a leadership shift at the Irvine-based company as it seeks to expand its commercial reach into retina treatments. She brings over 25 years of biopharmaceutical industry experience to guide the firm's strategic goals.
Neera Clase brings more than 25 years of biopharmaceutical experience to the firm. Her division manages the eye drop XDEMVY, which the company projects could reach $2 billion in peak annual sales.
The players
Neera Clase
She is the incoming Chief Commercial Officer at Tarsus Pharmaceuticals with over two decades of industry leadership experience.
Tarsus Pharmaceuticals
This Irvine-based biopharmaceutical firm focuses on developing therapies for eye conditions, including the FDA-approved product XDEMVY.
The details
Clase will lead commercial execution for the company's product line and its four clinical-stage pipeline programs. Her previous leadership background includes roles at Abbott Laboratories, Relypsa, Inc., and Acadia Pharmaceuticals.
Timeline
July 2026: Neera Clase began serving as interim CCO.
October 28, 2026: Tarsus announced the appointment of Neera Clase.
November 1, 2026: Neera Clase officially becomes Chief Commercial Officer.
Market Landscape
The appointment follows the FDA approval of XDEMVY, providing a foundation for commercial scale-up. This leadership transition signals a pivot toward capturing larger market share within the competitive ophthalmology sector.
The shift in commercial leadership could influence how the company promotes its current treatments to eye care specialists in the area. Customers may see changes in the availability or marketing strategies for products like the XDEMVY eye drop.
The takeaway
Clase's promotion highlights the growing importance of commercial expertise in guiding specialized biotech firms toward long-term profitability. Investors and industry watchers will focus on her ability to execute the company's ambitious revenue targets.
Further reading
For more on local leadership changes, visit People.
More information
Review the XDEMVY full prescribing information for detailed clinical data.
Live Poll
Do you trust that new corporate leadership will prioritize patient access to essential prescription medications?
